首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2048040

血液製品市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭格局分類，2021-2031年

Blood Product Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Region & Competition, 2021-2031F

出版日期: 2026年05月25日 | 出版商:

TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球血液製品市場預計將從 2025 年的 452.3 億美元大幅成長至 2031 年的 642.7 億美元，複合年成長率為 6.03%。

該市場涵蓋源自人類血液的治療性生物製藥，例如全血、紅血球、血小板和血漿，這些製品對輸血醫學和血液疾病的治療至關重要。其成長主要受全球慢性疾病（如癌症和血友病）發病率上升以及人口老化導致外科手術和創傷治療需求增加的驅動。這些持續存在的因素使得全球對安全且相容的血液成分的需求保持穩定，不受短期市場波動的影響。

市場概覽
預測期	2027-2031
市場規模：2025年	452.3億美元
市場規模：2031年	642.7億美元
複合年成長率：2026-2031年	6.03%
成長最快的細分市場	紅血球
最大的市場	北美洲

然而，儘管需求強勁，但血液產業在供應鏈可靠性和自願捐血持續參與方面仍面臨許多挑戰。頻繁且嚴重的血液短缺常常擾亂這些必需品的供應，尤其是在季節性時期和區域性危機期間，對營運帶來巨大挑戰。例如，美國血液中心發布的一份2025年報告指出，美國南部約25%的血液中心將面臨血液庫存不到一天供應的危機，凸顯了維持充足庫存水準的困難。這種情況可能會阻礙市場的永續成長，並限制患者獲得必要的治療。

市場促進因素

全球血液製品市場的主要驅動力是血液疾病和慢性病盛行率的不斷上升，這持續推高了對全血及其成分的需求。隨著癌症和貧血等疾病的日益普遍，醫療保健系統面臨更大的壓力，需要維持充足的紅血球和血小板供應，以用於支持治療和手術。例如，美國癌症協會於2025年1月發布的《2025年癌症事實與數據》報告預測，僅在美國就將新增313,780例前列腺癌病例，這表明需要腫瘤手術和輸血管理的患者群體正在不斷成長。這種流行病學負擔，尤其是在老齡化社會中，確保了對合適的血液製品（用於處理術中出血和化療引起的血球減少症）的穩定潛在需求，而不受季節性供應波動的影響。

同時，由於血漿衍生免疫球蛋白的需求不斷成長，市場正在經歷一場變革。血漿衍生免疫球蛋白已成為治療原發性免疫力缺乏缺陷疾病和自體免疫神經病變的必要療法。與傳統的全血輸注相比，這一領域的價值成長更為顯著，這主要得益於診斷能力的提升和免疫球蛋白療法適應症的擴大，而後者需要大規模的血漿分餾。根據《生物技術快訊》（Biotech Dispatch）2025年2月的報導報道，CSL Behring公司報告稱，其2024會計年度上半年的免疫球蛋白銷售額達到31.7億美元，同比成長15%，這主要得益於全球患者需求的成長。這一成長趨勢反映了整個行業的蓬勃發展。此外，Griffols公司在2025年2月公佈，其2024會計年度全年總銷售額成長10.3%，進一步印證了全球血液製品產業的強勁成長動能。

市場挑戰

全球血液製品市場成長的主要障礙在於供應鏈固有的不穩定性以及自願捐血的不穩定性。與市售藥品不同，血液製品市場直接依賴捐血率，形成了一個脆弱的系統，產品供應常常無法滿足臨床的迫切需求。這種依賴性導致血站運作極不穩定，因為血站需要努力維持基本治療所需的穩定庫存，阻礙了收入成長和市場可預測性。捐血率下降會擾亂整個價值鏈，導致市場萎縮而非擴張。

近期產業數據顯示庫存嚴重短缺，印證了這種營運上的脆弱性。例如，美國紅十字會在2024年8月報告稱，由於捐血活動的季節性波動，全國血液供應量在一個月內下降了超過25%。這種極端波動迫使醫療系統優先考慮庫存分配而非服務擴張，這直接阻礙了市場成長。因此，捐血參與率與患者需求之間持續存在的差距有效地限制了市場發展，使該行業無法充分利用全球血液製品需求的成長。

市場趨勢

全球血液製品市場正因病原體去除技術（PRT）的引入而重組。這些技術透過預先去活化血液成分中的病毒、細菌和寄生蟲，從根本上提高了安全標準。這項創新顯著降低了輸血相關感染疾病的風險，並在血小板和血漿中得到越來越廣泛的應用。因此，產業策略正從被動篩檢以應對新出現的生物威脅，轉向預防性病原體去活化。主要產業相關人員已證實，對這些安全增強技術的需求大幅成長，這一趨勢在對止血至關重要的纖維蛋白原複合物中尤為明顯。例如，Cerus公司在2025年11月報告稱，2025年第三季產品總銷售額達到5,270萬美元，年增15%。這主要歸功於其INTERCEPT血液系統的商業性化推廣。

同時，自動化採血系統的普及顯著提高了捐血者的採血量和營運效率。與傳統的人工方法相比，這些系統使醫療機構能夠收集更多特定成分，例如血漿和血小板。這些先進的血漿分離平台對於滿足全球日益成長的血漿療法需求至關重要，並透過提高採血速度有效緩解了捐血者數量限制所帶來的挑戰。這種透過自動化提高效率的策略性舉措，得益於關鍵採血領域的顯著成長。一個典型的例子是Hemonetics公司於2025年11月發布的2026年第二季財報，該財報顯示其血漿業務的有機銷售額成長了19%，凸顯了其先進的自動化採血技術迅速獲得了市場的認可。

The Global Blood Product Market is projected to expand significantly, rising from USD 45.23 billion in 2025 to USD 64.27 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 6.03%. This market involves therapeutic biological substances derived from human blood, such as whole blood, red blood cells, platelets, and plasma, which are essential for transfusion medicine and managing hematological conditions. Its growth is primarily fueled by the increasing worldwide incidence of chronic diseases like cancer and hemophilia, coupled with an aging population requiring more surgical procedures and trauma care. These ongoing factors create a consistent global demand for safe and compatible blood components, irrespective of short-term market fluctuations.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 45.23 Billion
Market Size 2031	USD 64.27 Billion
CAGR 2026-2031	6.03%
Fastest Growing Segment	Red Blood Cells
Largest Market	North America

However, despite this strong demand, the industry confronts considerable obstacles concerning supply chain reliability and the consistency of voluntary donor participation. Frequent and severe shortages often disrupt the availability of these crucial products, especially during seasonal periods or regional crises, posing substantial operational challenges. For instance, in 2025, America's Blood Centers reported that about 25% of blood centers in the southern United States had a critical supply of less than one day, underscoring the precariousness of maintaining adequate inventory. This situation can hinder sustained market growth and limit patient access to necessary treatments.

Market Driver

A primary factor propelling the global blood product market is the increasing prevalence of hematological disorders and chronic diseases, which consistently drive demand for whole blood and its components. As conditions like cancer and anemia become more widespread, healthcare systems are under greater pressure to maintain substantial supplies of red blood cells and platelets for supportive care and surgical procedures. For example, the American Cancer Society's 'Cancer Facts & Figures 2025' report, published in January 2025, projected 313,780 new prostate cancer cases in the United States alone, illustrating the growing patient population requiring oncological surgeries and transfusion management. This epidemiological burden, especially within aging populations, guarantees a steady baseline demand for compatible blood products to manage blood loss during surgery and cytopenia induced by chemotherapy, independent of seasonal supply variations.

Concurrently, the market is undergoing transformation due to the escalating demand for plasma-derived immunoglobulins, now crucial for treating primary immunodeficiencies and autoimmune neuropathies. This segment demonstrates significantly higher value growth compared to traditional whole-blood transfusions, spurred by improved diagnostic capabilities and more approved uses for immunoglobulin therapies, which necessitate large-scale plasma fractionation. According to a February 2025 Biotech Dispatch article, CSL Behring reported immunoglobulin sales of $3.17 billion in the first half of the fiscal year, marking a 15% increase driven by global patient needs. This particular growth trend reflects the overall vigor of the sector; moreover, Grifols confirmed the robust financial expansion of the global blood product industry, reporting a 10.3% total revenue increase for the full year 2024 in February 2025.

Market Challenge

The main obstacle hindering the growth of the Global Blood Product Market is the intrinsic volatility within its supply chain and the inconsistent nature of voluntary donor participation. Unlike commercially manufactured drugs, this market is directly dependent on human donation rates, forming a delicate system where product availability frequently falls short of strong clinical requirements. This reliance leads to considerable operational instability, as blood centers strive to uphold steady inventories for essential treatments, consequently impeding revenue growth and market predictability. Declining collection rates disrupt the entire value chain, causing market contraction instead of expansion.

This operational vulnerability is demonstrated by recent industry data showing significant inventory shortfalls. For example, the American Red Cross reported that in August 2024, the national blood supply dropped by over 25% in a single month due to seasonal fluctuations in donor activity. Such intense volatility compels healthcare systems to prioritize inventory rationing over service expansion, directly hindering the market's capacity to scale. Therefore, the ongoing disparity between donor turnout and patient demand effectively caps market progression, preventing the sector from fully leveraging the increasing global need for blood therapeutics.

Market Trends

The Global Blood Product Market is being reshaped by the integration of Pathogen Reduction Technologies (PRT), which are fundamentally enhancing safety standards by proactively inactivating viruses, bacteria, and parasites in blood components. This innovation significantly reduces the risk of transfusion-transmitted infections and is becoming increasingly common for platelets and plasma, shifting the industry's approach from reactive screening to preventative pathogen inactivation to guard against new biological threats. Key industry participants are observing a substantial increase in demand for these enhanced safety features, particularly for fibrinogen complexes vital in hemorrhage control. For instance, Cerus Corporation reported in November 2025 total product revenue of $52.7 million for the third quarter of 2025, a 15% year-over-year increase, largely attributable to the expanded commercial adoption of its INTERCEPT Blood System.

Concurrently, the widespread adoption of Automated Blood Collection Systems is significantly improving donor yield and operational efficiency. These systems enable centers to collect specific components such as plasma or platelets in much higher volumes compared to traditional manual methods. These advanced apheresis platforms are crucial for addressing the rising global demand for plasma-derived therapies, effectively mitigating limitations imposed by donor pool constraints through accelerated collection rates. This strategic move towards automated efficiency is underscored by considerable growth in key collection segments, as evidenced by Haemonetics Corporation's plasma business achieving a 19% organic revenue growth in its second-quarter fiscal 2026 earnings release in November 2025, highlighting the rapid market acceptance of its advanced automated collection technologies.

Key Market Players

CSL Limited
Takeda Pharmaceutical Company Limited
Octapharma AG
Grifols, S.A.
Kedrion S.p.A
Hualan Biological Vaccine Inc.
Mitsubishi Tanabe Pharma Corporation
Baxter International Inc.
Versiti, Inc.
Bio Products Laboratory Ltd.

Report Scope

In this report, the Global Blood Product Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Blood Product Market, By Type

Red Blood Cells
Platelets
Fresh Frozen Plasma
White Blood Cells
Others

Blood Product Market, By Application

Blood Station
Hospitals
Others

Blood Product Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Product Market.

Available Customizations:

Global Blood Product Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Blood Product Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Red Blood Cells, Platelets, Fresh Frozen Plasma, White Blood Cells, Others)
- 5.2.2. By Application (Blood Station, Hospitals, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2025)
5.3. Market Map

6. North America Blood Product Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Application
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Blood Product Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Application
- 6.3.2. Canada Blood Product Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Application
- 6.3.3. Mexico Blood Product Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Application

7. Europe Blood Product Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Application
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Blood Product Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Application
- 7.3.2. France Blood Product Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Application
- 7.3.3. United Kingdom Blood Product Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Application
- 7.3.4. Italy Blood Product Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Application
- 7.3.5. Spain Blood Product Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Application

8. Asia Pacific Blood Product Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Application
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Blood Product Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Application
- 8.3.2. India Blood Product Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Application
- 8.3.3. Japan Blood Product Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Application
- 8.3.4. South Korea Blood Product Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Application
- 8.3.5. Australia Blood Product Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Application

9. Middle East & Africa Blood Product Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Application
- 9.2.3. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Blood Product Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Application
- 9.3.2. UAE Blood Product Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Application
- 9.3.3. South Africa Blood Product Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Application

10. South America Blood Product Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Application
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Blood Product Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Application
- 10.3.2. Colombia Blood Product Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Application
- 10.3.3. Argentina Blood Product Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Application

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Blood Product Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. CSL Limited
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Takeda Pharmaceutical Company Limited
15.3. Octapharma AG
15.4. Grifols, S.A.
15.5. Kedrion S.p.A
15.6. Hualan Biological Vaccine Inc.
15.7. Mitsubishi Tanabe Pharma Corporation
15.8. Baxter International Inc.
15.9. Versiti, Inc.
15.10. Bio Products Laboratory Ltd.